Skip to main content
JINLING PHARMACEUTICAL CO.,LTD logo

JINLING PHARMACEUTICAL CO.,LTD — Investor Relations & Filings

Ticker · 000919 ISIN · CNE0000010W5 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,771 across all filing types
Latest filing 2021-11-11 Governance Information
Country CN China
Listing Shenzhen Stock Exchange 000919

About JINLING PHARMACEUTICAL CO.,LTD

https://www.jlyy1999.com

Jinling Pharmaceutical Co., Ltd. specializes in the research, development, manufacture, and sale of pharmaceutical products, with a focus on chemical drugs and traditional Chinese medicine preparations. The company’s product portfolio primarily targets cardiovascular and cerebrovascular diseases, anti-tumor treatments, and digestive system health. A prominent product in its lineup is the Mailuoning Injection, utilized for treating various vascular conditions. In addition to its manufacturing operations, the company is involved in the management and operation of medical institutions, integrating clinical services with pharmaceutical production. Its business model emphasizes the synergy between drug development and healthcare service delivery to provide integrated medical solutions.

Recent filings

Filing Released Lang Actions
金陵药业股份有限公司章程(2021年11月)
Governance Information Classification · 100% confidence The document is titled as the Articles of Association (章程) of Jinling Pharmaceutical Company Limited. It contains detailed provisions about the company's organization, shareholder rights, board structure, management, financial accounting, audit, and procedures for shareholder meetings. The content is focused on the company's internal governance rules, shareholder meeting procedures, board and management roles, and related corporate governance matters. There is no indication of financial statements, audit opinions, earnings data, or announcements of voting results. The document is a comprehensive governance document outlining the company's internal rules and structure. Therefore, it fits the category of Governance Information (CGR).
2021-11-11 Chinese
金陵药业股份有限公司董事会向经理层授权管理办法
Board/Management Information Classification · 95% confidence The document is titled as a management authorization method from the board of directors to the management team, detailing principles, scope, conditions, and procedures for delegation of authority within the company. It references company governance rules, legal regulations, and internal decision-making processes. There is no indication of financial data, audit results, voting outcomes, or report publication. The content focuses on internal board and management governance and delegation practices, which aligns with Board/Management Information filings rather than financial reports or regulatory announcements.
2021-11-11 Chinese
金陵药业股份有限公司关于拟签订合肥金陵天颐智慧养老项目招商引资协议的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the company's intention to sign an investment agreement for a new project, detailing the project overview, parties involved, investment scale, and related risks. It includes information about board approval but does not contain financial statements or detailed financial performance data. The document is a formal disclosure of a capital investment agreement and related project details, which fits the category of Capital/Financing Update (CAP). The document length is 4672 characters, which is sufficient for a detailed announcement but does not constitute a full financial report or annual/interim report. There is no indication that this is a report publication announcement or a regulatory filing fallback. Therefore, the classification is Capital/Financing Update (CAP).
2021-11-11 Chinese
金陵药业第八届董事会第十三次会议决议公告
Board/Management Information Classification · 100% confidence The document is a formal announcement of resolutions passed at the 13th meeting of the 8th Board of Directors of Jinling Pharmaceutical Co., Ltd. It details the meeting date, voting results, and references to related announcements and documents. The content focuses on board decisions, amendments to company bylaws, and authorization management, which are typical of board/management information disclosures. The document is short (1036 characters) and does not contain financial data or detailed reports, so it is not an annual report or interim report. It is not a shareholder voting result announcement since it pertains to board meeting resolutions, not shareholder votes. Therefore, the appropriate classification is Board/Management Information (MANG).
2021-11-11 Chinese
金陵药业股份有限公司关于孙公司注销完成的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement regarding the completion of the deregistration (注销) of a subsidiary company. It references a prior announcement (公告编号：2021-052) about the liquidation and deregistration process. The text states that the subsidiary is no longer included in consolidated financial statements and that this will not materially affect the company's operations. The document is brief (531 characters) and serves as an update on a corporate event rather than a detailed financial report or regulatory filing. It does not contain financial statements, audit information, or management discussion. It is not a report publication announcement since it does not mention a report being published or attached. The content fits best under Regulatory Filings (RNS) as a general corporate announcement that does not fit other specific categories.
2021-11-03 Chinese
2021年第三季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled '金陵药业股份有限公司 2021 年第三季度报告' which translates to 'Jinling Pharmaceutical Co., Ltd. 2021 Third Quarter Report'. It contains detailed financial data including balance sheets, profit and loss statements, cash flow statements, and notes on financial indicators for the third quarter of 2021. The document explicitly states it is a quarterly report and includes comprehensive financial statements and analysis for a period shorter than a full fiscal year. It is not an announcement or a brief summary but a full financial report. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q3 2021
2021-10-26 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.